TherapeuticsMD, Inc. (TXMD)
| Market Cap | 13.66M |
| Revenue (ttm) | 1.84M |
| Net Income (ttm) | -2.10M |
| Shares Out | 11.57M |
| EPS (ttm) | -0.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,462 |
| Open | 1.150 |
| Previous Close | 1.140 |
| Day's Range | 1.142 - 1.200 |
| 52-Week Range | 0.700 - 2.440 |
| Beta | 0.58 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2025 |
About TXMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. [Read more]
Financial Performance
In 2024, TherapeuticsMD's revenue was $1.76 million, an increase of 35.25% compared to the previous year's $1.30 million. Losses were -$2.18 million, -78.78% less than in 2023.
Financial StatementsNews
TherapeuticsMD Announces First Quarter 2025 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD Announces Full Year 2024 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD Announces Third Quarter 2024 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
The Dow Jones index closed higher by more than 450 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.
TherapeuticsMD Announces Second Quarter 2024 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD Announces First Quarter 2024 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD Announces Full Year 2023 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD Announces Third Quarter 2023 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD Announces Second Quarter 2023 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD: From Fallen And Forgotten To Cash Cow
TXMD is a pharmaceutical company that experienced a tremendous transformation in the last year, fully transforming into a royalty-only company. The company sold all its assets and paid down all its de...
TherapeuticsMD Announces First Quarter 2023 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for...
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced that it has com...
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced that it has ent...
TherapeuticsMD Announces Third Quarter 2022 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the third qu...
TherapeuticsMD Announces Additional $7 Million Private Placement
BOCA RATON, Fla.
TherapeuticsMD Announces $7 Million Private Placement
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women's healthcare company, announced today that it received a $7 mil...
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women's healthcare company, announced today the appointment of Dr. Br...
TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd on Q2 2022 Results - Earnings Call Transcript
TherapeuticsMD, Inc. (NASDAQ:TXMD) Q2 2022 Earnings Conference Call August 15, 2022 8:30 PM ET Company Participants Lisa Wilson - IR Hugh O'Dowd - CEO Michael Donegan - Interim CFO Mark Glickman - Ch...
TherapeuticsMD Announces Second Quarter 2022 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the Second Qua...
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it will report its second quar...
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women's healthcare company, announced today that it has received a $1...
Why TherapeuticsMD Shares Are Sinking Today?
Women's healthcare company TherapeuticsMD Inc (NASDAQ: TXMD) shares are falling as EW Healthcare Partners did not acquire the required majority of shares of TXMD through the previously announced tende...
TherapeuticsMD's stock falls 41% after tender offer expires
Shares of TherapeuticsMD Inc. TXMD, +8.67% tumbled 41.6% in premarket trading on Wednesday after the women's health company told investors that EW Healthcare Partners' planned acquisition of Therapeut...
TherapeuticsMD Announces Expiration of Tender Offer
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TXMD” or the “Company”) an innovative, leading women's healthcare company, announced today that Athene Merger, Inc., an affili...